Kim Saverno

Senior Director, US Health Economic and Outcomes Research, Medical Affairs, Incyte

Kim Saverno, PhD, RPh, is Senior Director of Health Economics and Outcomes Research (HEOR) within the department of U.S. Medical Affairs at Incyte, leading real-world evidence generation for Incyte’s lymphoma and oncology portfolio. With 20 years of research experience, she has overseen the design, analysis, and interpretation of numerous HEOR projects and studies including real-world analyses, economic models, and value-based contracting initiatives. She holds a BPharm from The Ohio State University and a PhD in pharmaceutical economics, policy, and outcomes from the University of Arizona. She also completed a postdoctoral fellowship with a focus on health technology assessment and personalized cancer medicine. She is a licensed U.S. pharmacist and worked in managed care pharmacy before pursuing a career in health outcomes research.

Fei Fei Liu

Executive Director, Global Health Economic and Outcomes Research, Cell Therapy, Bristol Myers Squibb

Fei Fei Liu is the Executive Director of Global Health Economics and Outcomes Research (HEOR), Cell Therapy at Bristol Myers Squibb, where she leads the US and worldwide HEOR evidence generation strategy across the company’s growing cell therapy portfolio. In her role, she oversees a team of HEOR leaders responsible for generating, synthesizing, and translating real-world insights that inform clinical development, regulatory strategy, market access, and patient outcomes worldwide. Fei Fei has been at the forefront of advancing real-world data capabilities in cell therapy. She spearheaded strategic initiatives and collaborations, enabling deeper characterization of patient journeys, comparative effectiveness analyses, and evidence generation that supports clinical decision-making and health system adoption. With a background and experience spanning evidence generation, organizational leadership, and strategic partnership, Fei Fei brings a pragmatic and forward-looking perspective to how RWE can shape the next era of cell therapy innovation. She is passionate about leveraging data to improve patient access, inform global strategy, and ensure that rapidly evolving cell therapies deliver meaningful impact in real-world settings.

Anthony Proli

Clinical Director, Flatiron Health

Anthony Proli, PharmD, BCPS, BCOP, is a Clinical Director of Oncology Real-World Evidence at Flatiron Health.  By background, Dr. Proli is an oncology pharmacist with 10+ years of oncology experience specifically in hematologic malignancies, and cellular therapy.  He has deep expertise in the generation and use of real-world data including the curation of clinical data models using both human and LLM-based data extraction, and designing retrospective research studies to support evidence generation for multiple use cases including regulatory and HTA submissions.Dr. Proli received his doctorate of pharmacy with honors from the University of Connecticut.  He completed post-graduate training in oncology pharmacy at Yale-New Haven Hospital.  Prior to joining Flatiron Health, Dr. Proli was a clinical pharmacy specialist at Memorial Sloan Kettering Cancer Center with the bone marrow transplant and cell therapy service, and served as the pharmacy lead for cellular therapy.

Ashwini Shewade

Principal Real World Data Scientist (Hematology), Product Development Data Sciences, Roche

Ashwini Shewade is a strategic leader in Real-World Data (RWD) and Real-World Evidence Generation with over 15 years of experience in the pharmaceuticals and diagnostics industry. Currently serving as a Principal Data Scientist in Product Development at Roche/Genentech, she leads RWD strategy for Non-Hodgkin Lymphoma, bringing transformative medicines including Lunsumio™, Columvi™ and Polivy® to patients. Notably, she led the first Roche team to engage the FDA and EMA on an RWD-based solution for a regulatory submission and developed the company’s playbook for RWD-based external controls. Ashwini’s multi-disciplinary expertise spans epidemiology, biostatistics, health economics, and data science across diverse therapeutic areas like Hematology, Oncology, Immunology and Metabolic Disorders. Ashwini holds an M.S. in Biostatistics and Health Economics and an M.Sc. in Mathematical Statistics. She has authored numerous peer-reviewed publications and has extensive experience in regulatory interactions discussing the use of real-world evidence.

Moderator

Ahmed Sawas

Medical Director, Flatiron Health

Dr. Ahmed Sawas, MD, is a Medical Director at Flatiron Health, where he leads the development of next-generation real-world data (RWD) capabilities to better capture the nuance and complexity of hematologic disease. He works closely with product, engineering, and data science teams—as well as leading academic and industry partners—to support the use of real-world evidence in the advancement of meaningful research and the acceleration of therapeutic development in oncology.Dr. Sawas received his MD from the State University of New York—Health Science Center at Brooklyn College of Medicine. He then completed his internship, residency, and fellowship at St. Vincent’s Catholic Medical Center and a fellowship in Hematology-Oncology at New York University Medical Center.Prior to joining Flatiron, Dr. Sawas served as an Assistant Professor at Columbia University Irving Medical Center, specializing in lymphoid malignancies and the development of novel immunotherapies.